|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.7759 - 0.8547|
|52-week range||0.7055 - 25.1300|
|Beta (5Y monthly)||0.55|
|PE ratio (TTM)||N/A|
|Earnings date||06 Nov 2023 - 10 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Regulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector.
FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint.
The heavy selling pressure might have exhausted for FibroGen (FGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.